OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Pharmacokinetics and Pharmacodynamics is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	40
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	34
Learning pharmacometric covariate model structures with symbolic regression networks	32
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	29
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	29
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	25
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	23
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	19
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	18
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	18
Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis	17
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	16
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	16
ADPO: automatic-differentiation-assisted parametric optimization	16
Informatics for toxicokinetics	15
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	15
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	15
Current practices for QSP model assessment: an IQ consortium survey	15
Imputation of missing clock times – application to procalcitonin concentration time course after birth	15